These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 8874986)

  • 41. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators.
    Flaker GC; Warnica JW; Sacks FM; Moyé LA; Davis BR; Rouleau JL; Webel RR; Pfeffer MA; Braunwald E
    J Am Coll Cardiol; 1999 Jul; 34(1):106-12. PubMed ID: 10399998
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expected versus observed survival in 3 large population studies with HMG-CoA reductase inhibitors.
    Naslafkih A; Sestier F
    J Insur Med; 2000; 32(3):155-62. PubMed ID: 15912915
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
    Nissen SE; Tuzcu EM; Schoenhagen P; Crowe T; Sasiela WJ; Tsai J; Orazem J; Magorien RD; O'Shaughnessy C; Ganz P;
    N Engl J Med; 2005 Jan; 352(1):29-38. PubMed ID: 15635110
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Limitation of atherosclerosis in coronary arteries with pravastatin (PLAC 1)].
    Mancini GB
    Rev Esp Cardiol; 1995; 48 Suppl 2():11-3. PubMed ID: 7569269
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Advances in treatment of cholesterol abnormalities. The role of HMG-CoA reductase inhibitors.
    Rackley CE
    Postgrad Med; 1996 Nov; 100(5):61-5, 70-2. PubMed ID: 8917325
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Beyond lipid lowering: the role of statins in vascular protection.
    Liao JK
    Int J Cardiol; 2002 Nov; 86(1):5-18. PubMed ID: 12243846
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
    Nissen SE; Nicholls SJ; Sipahi I; Libby P; Raichlen JS; Ballantyne CM; Davignon J; Erbel R; Fruchart JC; Tardif JC; Schoenhagen P; Crowe T; Cain V; Wolski K; Goormastic M; Tuzcu EM;
    JAMA; 2006 Apr; 295(13):1556-65. PubMed ID: 16533939
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Three-year follow-up results of angiographic intervention trial using an HMG-CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma (ATHEROMA) study.
    Yokoi H; Nobuyoshi M; Mitsudo K; Kawaguchi A; Yamamoto A;
    Circ J; 2005 Aug; 69(8):875-83. PubMed ID: 16041153
    [TBL] [Abstract][Full Text] [Related]  

  • 50. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS).
    de Groot E; Jukema JW; Montauban van Swijndregt AD; Zwinderman AH; Ackerstaff RG; van der Steen AF; Bom N; Lie KI; Bruschke AV
    J Am Coll Cardiol; 1998 Jun; 31(7):1561-7. PubMed ID: 9626835
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
    Martens LL; Guibert R
    Clin Ther; 1994; 16(6):1052-62; discussion 1036. PubMed ID: 7697684
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease.
    Hay JW; Yu WM; Ashraf T
    Pharmacoeconomics; 1999 Jan; 15(1):47-74. PubMed ID: 10345158
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Prevention of coronary heart disease--"evidence-based medicine" of antilipemic therapy].
    Schaefer JR; Herzum M; Maisch B
    Herz; 1999 Feb; 24(1):3-12. PubMed ID: 10093008
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lipid lowering drugs in atherosclerosis--the HMG-CoA reductase inhibitors.
    Mantell G
    Clin Exp Hypertens A; 1989; 11(5-6):927-41. PubMed ID: 2676263
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
    Garnett WR
    Am J Health Syst Pharm; 1995 Aug; 52(15):1639-45. PubMed ID: 7583826
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin.
    Maher VM; Thompson GR
    Q J Med; 1990 Feb; 74(274):165-75. PubMed ID: 2111917
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.
    Rosenson RS
    Am Heart J; 2006 Mar; 151(3):556-63. PubMed ID: 16504615
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current and future treatment of hyperlipidemia: the role of statins.
    Farnier M; Davignon J
    Am J Cardiol; 1998 Aug; 82(4B):3J-10J. PubMed ID: 9737640
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Results of recent large cholesterol-lowering trials and implications for clinical management.
    Gotto AM
    Am J Cardiol; 1997 Jun; 79(12):1663-6. PubMed ID: 9202359
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.
    Waters D; Higginson L; Gladstone P; Kimball B; Le May M; Boccuzzi SJ; Lespérance J
    Circulation; 1994 Mar; 89(3):959-68. PubMed ID: 8124836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.